Condition category
Mental and Behavioural Disorders
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Both cognitive behavior therapy (CBT) and paroxetine (PX) are the preferred treatments for social anxiety disorder (SAD). But in literature there have been divided opinions for the efficacy for combination of these treatments. This study intended to evaluate whether combination of CBT and PX would be superior to monotherapy of PX in the treatment of SAD. Design: Single centre, rater-blind, non randomised study. Participants: Consenting 40 adult participants who received CBT+PX or PX only assigned by treating clinicians. Outcome measures: Liebowitz Social Anxiety Scale (LSAS), Social Interaction Anxiety Scale (SIAS) and Fear of Negative Evaluation-Brief Version (BFNE) were assessed at baseline (0 week), and immediate post-treatment (16 -18 weeks for CBT+PX and 16-20 weeks for PX only), and at follow ups two months after post treatment. Results: Both treatment groups have significant difference in mean scores in all outcome measures in post treatment and follow-up stages compared with pre-treatment scores. But CBT+PX has a better treatment and maintenance gain as compared to PX alone in post-treatment and follow-up stages. Conclusions: In SAD management combinations ofSocial anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by a significant amount of fear in one or more social situations, causing considerable distress and impaired ability to function in at least some parts of daily life.[1]:15 These fears can be triggered by perceived or actual scrutiny from others. Individuals with social anxiety disorder fear negative evaluation from other people. CBT+PX is superior to PX alone and the treatment gains are also better maintained in former than later. There were no risk for participants in this study. We are thankful for the support received from the Quality of Life Research and Development Foundation (QoLReF) and the Institute of Insight, UK.

Background and study aims
Social anxiety disorder (SAD), also known as social phobia, is anxiety associated with fear in social situations. People with SAD fear being judged by other people. SAD causes distress and can stop people doing some normal activities of daily life. Cognitive behavior therapy (CBT) is a type of talking therapy that aims to challenge a person's negative thoughts, beliefs and attitudes. CBT and the antidepressant drug paroxetine (PX) are preferred treatments for social anxiety disorder (SAD). Research has not yet shown whether a combination of CBT and PX is more effective than PX alone. This study aims to investigate whether a combination of CBT and PX is better than PX alone in the treatment of SAD.

Who can participate?
Adults with a diagnosis of social phobia or SAD

What does the study involve?
The decision of whether the patients should have CBT and PX or PX alone was taken by the treatment team, including psychiatrists and psychologists, and took into account the preference of the participant. All patients received PX tablets and participants in the CBT+ PX group also received eight sessions of CBT, with each session lasting approximately one hour.

What are the possible benefits and risks of participating?
PX is a standard treatment for SAD and side effects are usually mild. There are no known risks of CBT. Participants might benefit from the additional CBT.

Where is the study run from?
The Mental Health Institute of SCB Medical College, Cuttack (India)

When is the study starting and how long is it expected to run for?
The study started from August 2017 to July 2019.

Who is funding the study?
The Mental Health Institute of SCB Medical College, Cuttack (India)

Who is the main contact?
1. Dr. Narendra nath Samantaray,
2. Nirupama Behera,

Trial website

Contact information



Primary contact

Dr Narendra Samantaray


Contact details

SCB Medical College

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number


Study information

Scientific title

Effectiveness of cognitive behavioral therapy on social anxiety disorder and fear of negative evaluation: A comparative study



Study hypothesis

There will be no significance difference in the treatment of social anxiety disorder between combined treatment with cognitive behavior therapy and paroxetine and paroxetine monotherapy.

Ethics approval

Approved 04/05/2018, Institutional Ethics Committee, S.C.B Medical College, Cuttack (Mangalabad, Cuttack-753007; no telephone number; no email), ref: 693/04.05.18; 626

Study design

Single-centre rater-blind quasi-randomized prospective observational study

Primary study design


Secondary study design

Cohort study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details to request a participant information sheet.


Social anxiety disorder


All the consecutive social anxiety disorder (SAD) patients attending the study centre were assessed and informed about both treatment modalities in SAD. Treatment decisions of paroxetine (PX) alone or PX+CBT were taken by the treating team, involving consultant psychiatrists and clinical psychologists following discussion with the patients. Patients were given choice to choose the treatment modalities. Assessment for recruitment continued from October 2017 and continued until February 2019 until there were 20 participants in each arm of the study. Final sample of 40 participants was available following 52 screenings for the study. The reasons for non-participation were long distance of travel to treatment centre and three were concerned about the stigma of repeated attendance in psychiatry.

CBT was based on Rapee’s model for SAD and used metaphor based conceptualization. The main steps in treatment were as follows: metaphor-based cognitive conceptualization, cognitive restructuring, exposure and behavioural experiments without use of safety behaviours and use of external focus of attention, and extensive home work sessions focusing both exposure and restructuring. In the CBT+PX group each participant were exposed to 8 sessions of CBT approximately 60 min. These were delivered by a master-level trainee pursuing an MPhil in clinical psychology and supervised by registered clinical psychologists. The other group received PX only. In both groups, the initial dosage of PX was 20 mg per day which later ranged from 20 to 60 mg/day. All the participants were followed up and monitored by consultant psychiatrists for the entire duration of the study.

Intervention type



Drug names

Primary outcome measure

1. Impact of social phobia assessed using the Liebowitz Social Anxiety Scale (LSAS) at baseline (0 week), and immediate post-treatment (16-18 weeks for CBT+PX and 16-20 weeks for PX only), and at follow-up 2 months after post treatment
2. Distress when meeting and talking with others assessed using the Social Interaction Anxiety Scale (SIAS) at baseline (0 week), and immediate post-treatment (16-18 weeks for CBT+PX and 16-20 weeks for PX only), and at follow-up 2 months after post treatment

Secondary outcome measures

Social anxiety assessed using the Fear of Negative Evaluation-Brief Version (BFNE) at baseline (0 week), and immediate post-treatment (16-18 weeks for CBT+PX and 16-20 weeks for PX only), and at follow-up 2 months after post treatment

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Diagnosis of social anxiety disorder based on ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research
2. Informed consent given
3. Aged 18 years or over

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Current level of severe depression with suicidal ideation
2. Substance dependence
3. Comorbid psychosis

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

S.C.B Medical College, Cuttack
MHI, SCB Medical College, Cuttack, Odisha

Sponsor information


Srirama Chandra Bhanja (SCB) Medical College

Sponsor details

+91 06712414359

Sponsor type

Hospital/treatment centre



Funder type

Hospital/treatment centre

Funder name

Srirama Chandra Bhanja (SCB) Medical College & Hospital

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

We intend to publish this study in a journal within 15 days from now.

IPD sharing statement:
The pre-treatment, post-treatment and follow-up datasets of outcome measures generated during the current study are available upon request by specifying the need from Nirupama Behera, Clinical psychology trainee, Dept. of Clinical Psychology, Mental Health Institute (Centre of Excellence), SCB Medical College & Hospital, Cuttack-753007. Email:

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

15/10/2019: Trial's existence confirmed by Institutional Ethics Committee, S.C.B Medical College, Cuttack.